Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study

This publication has 32 references indexed in Scilit:

• Improved survival in primary central nervous system lymphoma up to age 70 only: a population-based study on incidence, primary treatment and survival in the Netherlands, 1989–2015
  Leukemia, 2017
• Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology
  The Lancet Oncology, 2015
• Age, gender, and racial differences in incidence and survival in primary CNS lymphoma
  British Journal of Cancer, 2011
• High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial
  The Lancet Oncology, 2010
• High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial
  The Lancet, 2009
• Early relapses in primary CNS lymphoma after response to polychemotherapy without intraventricular treatment: results of a phase II study
  Journal of Neuro-Oncology, 2008
• Primary Central Nervous System Lymphoma: The Memorial Sloan-Kettering Cancer Center Prognostic Model
  Journal of Clinical Oncology, 2006
• High-Dose Methotrexate-Based Chemotherapy Followed by Consolidating Radiotherapy in Non–AIDS-Related Primary Central Nervous System Lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962
  Journal of Clinical Oncology, 2003
• Is Intrathecal Methotrexate Necessary in the Treatment of Primary CNS Lymphoma?
  Journal of Neuro-Oncology, 2002
• Effect of dose and repeat intravenous 24 hr infusions of methotrexate on cerebrospinal fluid availability in children with hematological malignancies
  European Journal of Cancer and Clinical Oncology, 1987